iCAD to Report Third Quarter 2024 Financial Results on November 13, 2024
iCAD (NASDAQ: ICAD), a provider of AI-powered cancer detection solutions, has scheduled its Q3 2024 financial results release for November 13, 2024, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day. Investors can access the call via toll-free number 877-545-0320 or international number 973-528-0002 using participant code 509249. A webcast will also be available.
iCAD (NASDAQ: ICAD), fornitore di soluzioni per la rilevazione del cancro basate su intelligenza artificiale, ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024 per il 13 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una call con gli investitori alle 16:30 ora orientale dello stesso giorno. Gli investitori possono accedere alla call tramite il numero verde 877-545-0320 o il numero internazionale 973-528-0002 utilizzando il codice partecipante 509249. Sarà disponibile anche una webcast.
iCAD (NASDAQ: ICAD), proveedor de soluciones de detección de cáncer impulsadas por inteligencia artificial, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el 13 de noviembre de 2024, después del cierre del mercado. La compañía realizará una llamada de conferencia a las 4:30 PM, hora del Este, el mismo día. Los inversores pueden acceder a la llamada a través del número gratuito 877-545-0320 o del número internacional 973-528-0002 utilizando el código de participante 509249. También estará disponible una transmisión en vivo.
iCAD (NASDAQ: ICAD), AI 기반 암 검출 솔루션 제공업체,는 2024년 3분기 재무 결과 발표를 2024년 11월 13일 시장 마감 후로 예정했습니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 개최할 것입니다. 투자자들은 무료 전화번호 877-545-0320 또는 국제 전화번호 973-528-0002로 참가 코드 509249를 사용하여 콜에 접속할 수 있습니다. 웹캐스트도 제공될 예정입니다.
iCAD (NASDAQ: ICAD), fournisseur de solutions de détection du cancer alimentées par l'intelligence artificielle, a prévu la publication de ses résultats financiers du T3 2024 pour le 13 novembre 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique à 16h30, heure de l'Est, le même jour. Les investisseurs peuvent accéder à l'appel via le numéro sans frais 877-545-0320 ou le numéro international 973-528-0002 en utilisant le code de participant 509249. Un webinaire sera également disponible.
iCAD (NASDAQ: ICAD), Anbieter von KI-gestützten Lösungen zur Krebsdiagnose, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für den 13. November 2024 nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten. Investoren können sich über die gebührenfreie Nummer 877-545-0320 oder die internationale Nummer 973-528-0002 mit dem Teilnehmercode 509249 in die Konferenz einwählen. Es wird auch einen Webcast geben.
- None.
- None.
NASHUA, N.H., Nov. 05, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024.
Earnings call details are as follows:
Toll Free: 877-545-0320
International: 973-528-0002
Participant Access Code: 509249
Webcast: https://www.webcaster4.com/Webcast/Page/2879/51509
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries:
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
FAQ
When will iCAD (ICAD) release Q3 2024 earnings?
What time is iCAD's (ICAD) Q3 2024 earnings call?
How can I access iCAD's (ICAD) Q3 2024 earnings call?
